Melanoma In Vivo Screen
Evaluate your melanoma therapeutics with our selection of specialized patient-derived xenograft (PDX) melanoma models, featuring BRAF mutations and models from patients treated with BRAF and checkpoint inhibitors
Why evaluate your therapeutic candidates in the Melanoma In Vivo Screen?
Drug development scientists have determined that patient-derived xenograft model selection can drive the success or failure of a preclinical study. It's critical to choose a partner with deeply characterized, clinically relevant Melanoma PDX models. Contact us today to advance your melanoma drug development project.
Clinically Relevant Models
A diverse bank of PDX models that strongly correlate with clinical outcomes
Cost Effective Platform
50% off of a parallel Standard of Care agent arm (selected by Champions)
Deeply Characterized Models
- Robust clinical data annotations
- NGS (RNAseq and WES) analysis
- Proteomics & phospho-proteomics
Melanoma PDX Model Responses Correlate to Patient Outcomes
Melanoma In Vivo Screen Drug Responses
SOC evaluation for vemurafenib conducted on two models CTG-0435 and CTG-0500 included in the screen.